Itraconazole for bronchiectasis with airway mold growth
Treatments studied
Part of Lungs & breathing clinical trials.
This Mayo Clinic study tests whether the oral antifungal drug itraconazole can help people with bronchiectasis who have mold growing in their airways. The goal is to see if it improves symptoms and reduces mold in the lungs.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older and seen at the Mayo Clinic mycobacterial and bronchiectasis clinic in Rochester.
- You have been diagnosed with bronchiectasis, a lung condition where airways are damaged and widened.
- In the last 3 months, a sputum (phlegm) test showed a lot of mold (or at least two different types of mold).
- You are not currently taking antibiotics or antifungal medications, and don't plan to start them soon.
- You must be able to cough up phlegm on your own at the first study visit.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a common antibiotic called azithromycin can help prevent flare-ups (sudden worsening) of bronchiectasis—a lung condition where airways become permanently enlarged and damaged. Patients will take azithromycin or a placebo for 12 months to see if it reduces how often they get sick.
This trial tests whether a new medication, BI 1291583, can help people with bronchiectasis reduce lung infections and symptoms. You may join if you have had at least one or two lung flare-ups in the past year.
This trial tests if a new drug, GSK3862995B, is safe and effective for adults with bronchiectasis. It might help reduce lung infections and improve symptoms.
This trial tests different combinations of medicines for people hospitalized with a serious fungal infection called histoplasmosis. The goal is to find the most effective way to treat the infection and help patients recover faster.
This study tests whether a combination of inhaled liposomal amphotericin B (Ambisome) plus itraconazole works better for chronic pulmonary aspergillosis (CPA). It may help control long-term Aspergillus lung infection and symptoms.
This trial compares itraconazole taken by mouth alone versus itraconazole plus steroid pills in people who have a mix of two Aspergillus lung conditions. It aims to see which approach works better to control symptoms and lung changes caused by Aspergillus infection.
Hear when a new Bronchiectasis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.